About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Nf2+
wild type
MGI:2431593
Summary 8 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
ht1
 		Nf2tm1Tyj/Nf2+ either: (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) or (involves: 129S2/SvPas * C57BL/6J) MGI:2447459
ht2
 		Nf2tm1Gth/Nf2+ involves: 129P2/OlaHsd * FVB/N MGI:2447472
ht3
 		Nf2tm2.1Gth/Nf2+ involves: 129P2/OlaHsd * FVB/N MGI:2447474
ht4
 		Nf2tm2Gvn/Nf2+ Not Specified MGI:5504375
cn5
 		Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2+ 		involves: 129P2/OlaHsd MGI:3850444
cn6
 		Nf2tm2Gth/Nf2+
Trp53tm1Brn/Trp53tm1Brn 		involves: 129P2/OlaHsd * 129S7/SvEvBrd MGI:3850446
cn7
 		Nf2tm2Gth/Nf2+
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)3Brn/0 		involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N MGI:3850410
cn8
 		Nf2tm2Gth/Nf2+
Tg(Mpz-cre)#Brn/0 		involves: 129P2/OlaHsd * FVB/N MGI:3850405


Genotype
MGI:2447459
ht1
Allelic
Composition		 Nf2tm1Tyj/Nf2+
Genetic
Background		 either: (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) or (involves: 129S2/SvPas * C57BL/6J)
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2tm1Tyj mutation (1 available); any Nf2 mutation (65 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
neoplasm ( J:47282 )
N
• schwannomas, meningiomas, or ependymomas were not detected
increased malignant tumor incidence ( J:47282 )
• increased incidence of highly metastatic tumors, including osteosarcoma, lymphoma, lung adenocarcinomas, hepatocellular carcinoma and fibrosarcoma
• osteosarcoma frequency was higher in females and the frequency of fibrosarcomas was higher in males

respiratory system

skeleton

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
NOT familial meningioma DOID:4586 J:47282




Genotype
MGI:2447472
ht2
Allelic
Composition		 Nf2tm1Gth/Nf2+
Genetic
Background		 involves: 129P2/OlaHsd * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2tm1Gth mutation (1 available); any Nf2 mutation (65 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
endocrine/exocrine glands
increased fibroadenoma incidence ( J:63264 )
• 13% of mice exhibit fibroadenoma in the mammary gland

neoplasm
neoplasm ( J:63264 )
N
• mice do not develop schwannoma, meningioma or other NF2-associated tumors
increased fibroadenoma incidence ( J:63264 )
• 13% of mice exhibit fibroadenoma in the mammary gland
osseous metaplasia ( J:63264 )
• mice exhibit osseous metaplasia in the lung, brain, kidney, and nasal mucosa
increased neurofibroma incidence ( J:63264 )
• 6% of mice develop neurofibroma
increased renal carcinoma incidence ( J:63264 )
• 6% of mice develop anaplastic carcinoma in the kidney
increased sarcoma incidence ( J:63264 )
• 13% of mice develop carcino-sarcoma in the mammary gland
increased neurofibrosarcoma incidence ( J:63264 )
• 6% of mice develop neurofibrosarcoma with 2 of 7 metastasizing to the liver
increased mesothelioma incidence ( J:63264 )
• 6% of mice develop mesothelioma
increased osteoma incidence ( J:63264 )
• 50% of mice develop osteoma

integument
increased fibroadenoma incidence ( J:63264 )
• 13% of mice exhibit fibroadenoma in the mammary gland

skeleton
abnormal tooth development ( J:63264 )
• 6% of mice exhibit odontoblastic hyperplasia
increased osteoma incidence ( J:63264 )
• 50% of mice develop osteoma
abnormal osteoblast morphology ( J:63264 )
• osteoblastic hyperplasia in 44% of mice

renal/urinary system
increased renal carcinoma incidence ( J:63264 )
• 6% of mice develop anaplastic carcinoma in the kidney
abnormal renal tubule morphology ( J:63264 )
• 38% of mice exhibit renal tubular cell hyperplasia

respiratory system

nervous system
nervous system phenotype ( J:63264 )
N
• mice exhibit normal Schwann cell proliferation
increased neurofibroma incidence ( J:63264 )
• 6% of mice develop neurofibroma
increased neurofibrosarcoma incidence ( J:63264 )
• 6% of mice develop neurofibrosarcoma with 2 of 7 metastasizing to the liver

craniofacial
abnormal tooth development ( J:63264 )
• 6% of mice exhibit odontoblastic hyperplasia

growth/size/body
abnormal tooth development ( J:63264 )
• 6% of mice exhibit odontoblastic hyperplasia




Genotype
MGI:2447474
ht3
Allelic
Composition		 Nf2tm2.1Gth/Nf2+
Genetic
Background		 involves: 129P2/OlaHsd * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2tm2.1Gth mutation (0 available); any Nf2 mutation (65 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
neoplasm ( J:63264 )
N
• mice do not develop schwannoma, meningioma or other NF2 associated tumors
increased fibrosarcoma incidence ( J:63264 )
• in 43% of mice with 1 of 3 metastasizing to the liver
increased osteoma incidence ( J:63264 )
• 29% of mice develop osteoma

respiratory system

skeleton
increased osteoma incidence ( J:63264 )
• 29% of mice develop osteoma

nervous system
nervous system phenotype ( J:63264 )
N
• mice exhibit normal Schwann cell proliferation




Genotype
MGI:5504375
ht4
Allelic
Composition		 Nf2tm2Gvn/Nf2+
Genetic
Background		 Not Specified
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2tm2Gvn mutation (1 available); any Nf2 mutation (65 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
nervous system
abnormal axon morphology ( J:197562 )
• axonal shrinkage

behavior/neurological
impaired coordination ( J:197562 )
• reduced latency to fall from a rotarod




Genotype
MGI:3850444
cn5
Allelic
Composition		 Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2+
Genetic
Background		 involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm2Brn mutation (2 available); any Cdkn2a mutation (62 available)
Nf2tm2Gth mutation (3 available); any Nf2 mutation (65 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:132943 )
• following adenoviral cre treatment, median survival time is 410 days

neoplasm
increased tumor incidence ( J:132943 )
• following adenoviral cre treatment, 34% of mice develop thoracic tumors (including malignant mesotheliomas, 14 of 41) with a longer latency than in mice homozygous for all alleles
• following adenoviral cre treatment, 24% of mice develop aspecific tumors not induced by adeno-cre treatment
increased uterus leiomyoma incidence ( J:132943 )
• in 17% of mice following adenoviral cre treatment
increased leukemia incidence ( J:132943 )
• following adenoviral cre treatment, 54% of mice develop monocytic myeloid leukemias

muscle
increased uterus leiomyoma incidence ( J:132943 )
• in 17% of mice following adenoviral cre treatment

reproductive system
increased uterus leiomyoma incidence ( J:132943 )
• in 17% of mice following adenoviral cre treatment




Genotype
MGI:3850446
cn6
Allelic
Composition		 Nf2tm2Gth/Nf2+
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background		 involves: 129P2/OlaHsd * 129S7/SvEvBrd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2tm2Gth mutation (3 available); any Nf2 mutation (65 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (232 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:132943 )
• following adenoviral cre treatment, median survival time is 215 days

neoplasm
increased tumor incidence ( J:132943 )
• following adenoviral cre treatment, 62% of mice develop thoracic tumors (including malignant mesothelimas, 20 of 34; and schwannomas, 1 of 34) with a longer latency than in mice homozygous for all alleles
• following adenoviral cre treatment, 21% of mice develop aspecific tumors not induced by adeno-cre treatment
increased uterus leiomyoma incidence ( J:132943 )
• in 9% of mice following adenoviral cre treatment
increased leukemia incidence ( J:132943 )
• following adenoviral cre treatment, 9% of mice develop monocytic myeloid leukemias

reproductive system
increased uterus leiomyoma incidence ( J:132943 )
• in 9% of mice following adenoviral cre treatment

muscle
increased uterus leiomyoma incidence ( J:132943 )
• in 9% of mice following adenoviral cre treatment

nervous system




Genotype
MGI:3850410
cn7
Allelic
Composition		 Nf2tm2Gth/Nf2+
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)3Brn/0
Genetic
Background		 involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2tm2Gth mutation (3 available); any Nf2 mutation (65 available)
Tg(Mpz-cre)3Brn mutation (0 available)
Trp53tm1Brd mutation (5 available); any Trp53 mutation (232 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:92413 )
• mice exhibit a decrease in survival rate when the Nf2 and Trp53 alleles are carried in cis as opposed to trans, but live longer than conditional mutants carrying Tg(P0-Cre)2Gth

neoplasm
increased neurofibrosarcoma incidence ( J:92413 )
• between 3.5 and 13.5 months,19% of mice develop malignant peripheral nerve sheath tumors when the Nf2 and Trp53 alleles are carried in cis
• however, no tumors form in mice when the Nf2 and Trp53 alleles are carried in trans
increased skeletal tumor incidence ( J:92413 )
• when the Nf2 and Trp53 alleles are carried in trans mice develop osteogenic tumors not restricted to neural crest-derived bone
increased osteosarcoma incidence ( J:92413 )
• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis
increased osteoma incidence ( J:92413 )
• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis

skeleton
increased skeletal tumor incidence ( J:92413 )
• when the Nf2 and Trp53 alleles are carried in trans mice develop osteogenic tumors not restricted to neural crest-derived bone
increased osteosarcoma incidence ( J:92413 )
• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis
increased osteoma incidence ( J:92413 )
• 81% of mice develop osteogenic (osteomas and osteosarcomas) tumors when the Nf2 and Trp53 alleles are carried in cis

nervous system
increased neurofibrosarcoma incidence ( J:92413 )
• between 3.5 and 13.5 months,19% of mice develop malignant peripheral nerve sheath tumors when the Nf2 and Trp53 alleles are carried in cis
• however, no tumors form in mice when the Nf2 and Trp53 alleles are carried in trans




Genotype
MGI:3850405
cn8
Allelic
Composition		 Nf2tm2Gth/Nf2+
Tg(Mpz-cre)#Brn/0
Genetic
Background		 involves: 129P2/OlaHsd * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nf2tm2Gth mutation (3 available); any Nf2 mutation (65 available)
Tg(Mpz-cre)#Brn mutation (0 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
endocrine/exocrine glands
increased fibroadenoma incidence ( J:63264 )
• 6% of mice exhibit fibroadenoma in the mammary gland

neoplasm
increased fibroadenoma incidence ( J:63264 )
• 6% of mice exhibit fibroadenoma in the mammary gland
increased osteoma incidence ( J:63264 )
• 6% of mice develop osteoma

integument
increased fibroadenoma incidence ( J:63264 )
• 6% of mice exhibit fibroadenoma in the mammary gland

nervous system
nervous system phenotype ( J:63264 )
N
• mice exhibit normal Schwann cell proliferation

respiratory system

craniofacial
abnormal tooth development ( J:63264 )
• 6% of mice exhibit odontoblastic hyperplasia

skeleton
abnormal tooth development ( J:63264 )
• 6% of mice exhibit odontoblastic hyperplasia
increased osteoma incidence ( J:63264 )
• 6% of mice develop osteoma

growth/size/body
abnormal tooth development ( J:63264 )
• 6% of mice exhibit odontoblastic hyperplasia




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
05/21/2024
MGI 6.23 		The Jackson Laboratory